Phase 1, Open-Label Study of Autologous SIRPA-low Macrophages (SIRPant-M) a cellular therapeutic product Administered by Intratumoral Injection Alone or in Combination with Focal External-Beam Radiotherapy in Participants with Relapsed or Refractory Non-Hodgkin’s Lymphoma